Here is how Zai Lab Limited performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Product Revenue- ZEJULA: $48.23 million versus ...
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and ...
GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...
The entrance to the Rolls Building, which houses the Business and Property Courts of England and Wales. A court in the UK has said that GSK should pay AstraZeneca a higher royalty rate on sales of ...
GlaxoSmithKline raised eyebrows last year when it paid $5.1 billion for Tesaro and its PARP inhibitor Zejula, amid suggestions it had paid too much. Now, a positive phase 3 trial for the drug will ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback